Integer Holdings Co. (NYSE:ITGR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Integer Holdings Co. (NYSE:ITGR) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $120.50.

Several brokerages have recently commented on ITGR. Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. CL King initiated coverage on shares of Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective for the company. KeyCorp upped their price objective on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a report on Tuesday, April 9th. Finally, Benchmark raised their target price on shares of Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th.

Integer Stock Performance

NYSE ITGR opened at $111.25 on Friday. The firm’s fifty day moving average price is $112.91 and its two-hundred day moving average price is $99.57. Integer has a 1 year low of $69.40 and a 1 year high of $123.99. The firm has a market capitalization of $3.73 billion, a P/E ratio of 41.36, a price-to-earnings-growth ratio of 1.63 and a beta of 1.10. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The company had revenue of $413.15 million for the quarter, compared to analysts’ expectations of $409.04 million. During the same period in the prior year, the firm earned $1.11 EPS. Integer’s quarterly revenue was up 10.9% compared to the same quarter last year. As a group, research analysts anticipate that Integer will post 5.31 EPS for the current year.

Institutional Investors Weigh In On Integer

A number of institutional investors have recently modified their holdings of ITGR. Blue Trust Inc. raised its stake in Integer by 483.3% in the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 377 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Integer in the fourth quarter valued at approximately $67,000. Emerald Mutual Fund Advisers Trust increased its stake in Integer by 66.6% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider’s stock worth $115,000 after acquiring an additional 584 shares during the period. Van ECK Associates Corp raised its holdings in Integer by 22.0% in the 3rd quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider’s stock valued at $136,000 after acquiring an additional 313 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Integer by 10.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 132 shares during the period. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.